As tumor glucose metabolism clinically assessed by FDG PET is associated with the expression of glucose transporters (GLUT) and glycolysis pathways [9–11], gene signatures of GLUT and glycolysis were used for defining glucose metabolic profiles of the tumors. The gene discussed is SLC2A1; the disease is neoplasm.